Cat. No. 3831
Chemical Name: (2E,4E,6Z)-3-Methyl-7-(5,6,7,8-tetr
Biological ActivityNovel RXR:PPARγ agonist; sensitizes PPARγ by enhancing its ligand binding activity. Also activates RXR:RAR and RXR:PPARα heterodimers in cotransfection assays. Displays selectivity over other permissive heterodimers such as RXR:LXRα and RXR:BAR/FXR. Exhibits antidiabetic properties in vivo.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Safety Data Sheet
Sato et al (2010) The "Phantom Effect" of the rexinoid LG100754: structural and functional insights. PLoS One 5 e15119. PMID: 21152046.
Germain et al (2006) International union of pharmacology LXIII. Retinoid X receptors. Pharmacol.Rev. 58 760. PMID: 17132853.
Forman (2002) The antidiabetic agent LG100754 sensitizes cells to low concentrations of peroxisome proliferator-activated receptor γ ligands. J.Biol.Chem. 277 12503. PMID: 11877384.
Cesario et al (2001) The retinoid LG100754 is a novel RXR:PPARγ agonist and decreases glucose levels in vivo. Mol.Endocrinol. 15 1360. PMID: 11463859.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses LG 100754 from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: LG 100754, supplier, LG100754, selective, retinoid, x, receptors, RXR, nuclear, receptors, ppar, peroxisome, proliferator, activated, receptors, PPARgamma, PPARg, PPARγ, agonists, sensitizers, Tocris Bioscience, Retinoid X Receptor products
Find multiple products by catalog number
New Products in this Area
Steroid receptor coactivator 3 (SRC-3) inhibitorSR 0987
T cell-specific RORγ (RORγt) agonistWAY 252623
Potent LXR agonistSR 9009
Rev-Erbα/β agonistSR 9238
Potent and selective LXR inverse agonistIP7e
Potent Nurr1 activatorBexarotene
Potent and selective RXR agonistGSK 2033
Potent LXR antagonist
September 14, 2016